Plasma endocannabinoid levels in multiple sclerosis

CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity

Giovanni Marsicano, Sharon Goodenough, Krisztina Monory et al. · Science · 2003 · 1.2K citations

Cb1 Cannabinoid Receptors, Neurotransmission, Cannabinoid Pharmacology +18

A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol

Jacqueline L. Blankman, Gabriel M. Simon, Benjamin F. Cravatt · Chemistry & Biology · 2007 · 1.2K citations · Full text

Cannabis Use, Neurodegenerative Diseases, Comprehensive Profile +13

The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide

Jesse Lo Verme, Jin Fu, Giuseppe Astarita et al. · Molecular Pharmacology · 2004 · 865 citations · Full text

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

John Zajicek, Patrick J. Fox, Hilary Sanders et al. · The Lancet · 2003 · 819 citations

Cannabis Use, Health Sciences, Neurological Disorder +11

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

David Rog, Turo Nurmikko, Tim Friede et al. · Neurology · 2005 · 667 citations